Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever

[1]  M. Brown,et al.  Genome-wide association study in Turkish and Iranian populations identify rare familial Mediterranean fever gene (MEFV) polymorphisms associated with ankylosing spondylitis , 2019, PLoS genetics.

[2]  Ö. Varan,et al.  Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis , 2019, Modern rheumatology.

[3]  H. Ozdogan,et al.  Familial Mediterranean Fever. , 2019, Presse medicale.

[4]  H. Lorenz,et al.  IL1-blocking therapy in colchicine-resistant familial Mediterranean fever , 2018, European journal of rheumatology.

[5]  N. Seyahi,et al.  Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever , 2018, Clinical transplantation.

[6]  A. Erden,et al.  Nationwide Experience With Off‐Label Use of Interleukin‐1 Targeting Treatment in Familial Mediterranean Fever Patients , 2018, Arthritis care & research.

[7]  J. Theis,et al.  Pathology and diagnosis of renal non-AL amyloidosis , 2018, Journal of Nephrology.

[8]  P. Hawkins,et al.  International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors , 2017, Rheumatology.

[9]  H. Ozdogan,et al.  Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever , 2017, Orphanet Journal of Rare Diseases.

[10]  M. Yildizgoren,et al.  Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever , 2017, Modern rheumatology.

[11]  O. Küçükşahin,et al.  Anakinra use during pregnancy: Report of a case with Familial Mediterranean Fever and infertility. , 2017, European journal of rheumatology.

[12]  K. Migita,et al.  Biologic therapy in familial Mediterranean fever , 2016, Modern rheumatology.

[13]  P. Messiaen,et al.  Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature , 2016, Biologics : targets & therapy.

[14]  A. Gül.  Approach to the patients with inadequate response to colchicine in familial Mediterranean fever. , 2016, Best practice & research. Clinical rheumatology.

[15]  D. Kastner,et al.  EULAR recommendations for the management of familial Mediterranean fever , 2016, Annals of the rheumatic diseases.

[16]  S. Ozen,et al.  Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases , 2016, Pediatric Nephrology.

[17]  M. Eki̇m,et al.  Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis , 2016, Clinical Rheumatology.

[18]  M. Birlik,et al.  Familial Mediterranean fever: An updated review. , 2014, European journal of rheumatology.

[19]  R. Gershoni-baruch,et al.  Evidence-based recommendations for the practical management of Familial Mediterranean Fever. , 2013, Seminars in arthritis and rheumatism.

[20]  A. Bakkaloğlu,et al.  Familial Mediterranean Fever (FMF) in Turkey: Results of a Nationwide Multicenter Study , 2005, Medicine.

[21]  H. Ozdogan,et al.  Increased frequency of familial Mediterranean fever in Central Anatolia, Turkey. , 2004, Clinical and experimental rheumatology.